{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:00:09Z","timestamp":1790704809907,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"crossref","award":["R184-A11806"],"award-info":[{"award-number":["R184-A11806"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["Empowering Cancer Immunotherapy in Denmark"],"award-info":[{"award-number":["Empowering Cancer Immunotherapy in Denmark"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00262-020-02760-z","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T10:06:01Z","timestamp":1604916361000},"page":"1771-1776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-1793","authenticated-orcid":false,"given":"Mario","family":"Presti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-4287","authenticated-orcid":false,"given":"Marie Christine Wulff","family":"Westergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-6750","authenticated-orcid":false,"given":"Arianna","family":"Draghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-2466","authenticated-orcid":false,"given":"Christopher Aled","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Gokuldass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"2760_CR1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.359.6382.1344","volume":"359","author":"PN Kelly","year":"2018","unstructured":"Kelly PN (2018) Special section the cancer immunotherapy revolution. Science 359:1344\u20131345. https:\/\/doi.org\/10.1126\/science.359.6382.1344","journal-title":"Science"},{"key":"2760_CR2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086","journal-title":"Cancer Discov"},{"key":"2760_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife BT, Pauken KE, Eagar TN et al (2009) Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10:1185\u20131192. https:\/\/doi.org\/10.1038\/ni.1790","journal-title":"Nat Immunol"},{"key":"2760_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"2760_CR5","unstructured":"IQVIA (2019) Global oncology trends 2019. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2019. Accessed 28 Oct 2020"},{"key":"2760_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim 6:38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Prim"},{"key":"2760_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ijc.32080","volume":"145","author":"A Draghi","year":"2019","unstructured":"Draghi A, Borch TH, Radic HD et al (2019) Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer 145:1408\u20131413. https:\/\/doi.org\/10.1002\/ijc.32080","journal-title":"Int J Cancer"},{"key":"2760_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","volume":"53","author":"N Acharya","year":"2020","unstructured":"Acharya N, Madi A, Zhang H et al (2020) Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment. Immunity 53:658-671.e6. https:\/\/doi.org\/10.1016\/j.immuni.2020.08.005","journal-title":"Immunity"},{"key":"2760_CR9","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E et al (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen. Clin Cancer Res 22:3734\u20133745. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1879","journal-title":"Clin Cancer Res"},{"key":"2760_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/annonc\/mdy139","volume":"29","author":"R Andersen","year":"2018","unstructured":"Andersen R, Borch TH, Draghi A et al (2018) T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Ann Oncol 29:1575\u20131581. https:\/\/doi.org\/10.1093\/annonc\/mdy139","journal-title":"Ann Oncol"},{"issue":"1","key":"2760_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12916-019-1323-8","volume":"17","author":"L Pouillon","year":"2019","unstructured":"Pouillon L, Vermeire S, Bossuyt P (2019) Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med 17(1):89. https:\/\/doi.org\/10.1186\/s12916-019-1323-8","journal-title":"BMC Med"},{"key":"2760_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5414\/CP201819","volume":"51","author":"X Zhang","year":"2013","unstructured":"Zhang X, Georgy A, Rowell L (2013) Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes in healthy subjects. Int J Clin Pharmacol Ther 51:443\u2013455. https:\/\/doi.org\/10.5414\/CP201819","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2760_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1208\/s12248-008-9038-3","volume":"10","author":"J Xu","year":"2008","unstructured":"Xu J, Winkler J, Sabarinath SN, Derendorf H (2008) Assessment of the impact of dosing time on the pharmacokinetics\/pharmacodynamics of prednisolone. AAPS J 10:331\u2013341. https:\/\/doi.org\/10.1208\/s12248-008-9038-3","journal-title":"AAPS J"},{"key":"2760_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818759930","author":"A Carlsen","year":"2018","unstructured":"Carlsen A, Omdal R, Leitao K\u00d8 et al (2018) Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn\u2019s disease. Ther Adv Gastroenterol. https:\/\/doi.org\/10.1177\/1756284818759930","journal-title":"Ther Adv Gastroenterol"},{"key":"2760_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/01.tp.0000253756.69243.65","volume":"83","author":"GE Koehl","year":"2007","unstructured":"Koehl GE, Wagner F, Stoeltzing O et al (2007) Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 83:607\u2013614. https:\/\/doi.org\/10.1097\/01.tp.0000253756.69243.65","journal-title":"Transplantation"},{"key":"2760_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623\u2013653","journal-title":"Clin Pharmacokinet"},{"key":"2760_CR17","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00262-020-02555-2","volume":"69","author":"IS Okoye","year":"2020","unstructured":"Okoye IS, Xu L, Walker J, Elahi S (2020) The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. Cancer Immunol Immunother 69:1423\u20131436. https:\/\/doi.org\/10.1007\/s00262-020-02555-2","journal-title":"Cancer Immunol Immunother"},{"key":"2760_CR18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1177\/0091270003258651","volume":"43","author":"DE Mager","year":"2003","unstructured":"Mager DE, Lin SX, Blum RA et al (2003) Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol 43:1216\u20131227. https:\/\/doi.org\/10.1177\/0091270003258651","journal-title":"J Clin Pharmacol"},{"key":"2760_CR19","unstructured":"Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire - Annals of Oncology. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(20)34468-9\/abstract. Accessed 4 May 2020"},{"key":"2760_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 7:341","journal-title":"J Immunother Cancer"},{"key":"2760_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 6:519\u2013527. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5570","journal-title":"JAMA Oncol"},{"key":"2760_CR22","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Stephen Hodi F et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807\u20133814. https:\/\/doi.org\/10.1200\/JCO.2017.73.2289","journal-title":"J Clin Oncol"},{"key":"2760_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","volume":"569","author":"E Perez-Ruiz","year":"2019","unstructured":"Perez-Ruiz E, Minute L, Otano I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569:428\u2013432. https:\/\/doi.org\/10.1038\/s41586-019-1162-y","journal-title":"Nature"},{"key":"2760_CR24","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer. J Clin Oncol 36:2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"2760_CR25","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","volume":"26","author":"RJ Verheijden","year":"2020","unstructured":"Verheijden RJ, May AM, Blank CU et al (2020) Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry. Clin Cancer Res 26:2268\u20132274. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3322","journal-title":"Clin Cancer Res"},{"key":"2760_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Wang X et al (2019) Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7:93. https:\/\/doi.org\/10.1186\/s40425-019-0577-1","journal-title":"J Immunother Cancer"},{"key":"2760_CR27","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/1078155218793709","volume":"25","author":"T Beardslee","year":"2019","unstructured":"Beardslee T, Draper A, Kudchadkar R (2019) Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor a therapy. J Oncol Pharm Pract 25:1275\u20131281. https:\/\/doi.org\/10.1177\/1078155218793709","journal-title":"J Oncol Pharm Pract"},{"key":"2760_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2407-5-4","volume":"5","author":"T Engl","year":"2005","unstructured":"Engl T, Makarevi\u0107 J, Relja B et al (2005) Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 5:4. https:\/\/doi.org\/10.1186\/1471-2407-5-4","journal-title":"BMC Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02760-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02760-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T04:05:23Z","timestamp":1621656323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02760-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2760"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02760-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"18 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Marco Donia has received honoraria for lectures from Roche and Novartis (past 2\u00a0years); Inge Marie Svane has received honoraria for consultancies and lectures from Novartis, Roche, Merck, and Bristol-Myers Squibb; a restricted research grant from Novartis; and financial support for attending symposia from Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}